CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Volumadevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02342223
NCT02342223Phase 1Completed
CompareCT.gov

Voluma Treatment of HIV Facial Lipoatrophy

Jared Jagdeo, MD, MS·interventional·Posted Jan 19, 2015·Updated Jan 16, 2017

In Brief

A Phase 1 clinical trial evaluating Voluma for HIV Facial Lipoatrophy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment of facial lipoatrophy in patients with HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Facial Lipoatrophy
CountriesUnited States
CollaboratorsAllergan, VA Northern California Health Care System, East Bay Institute for Research and Education

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 19, 2015
Enrollment StartFeb 1, 2015
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.5 years ago

Interventions

Volumadevice